Collaboration. Acceleration. Results.
Myelin Repair Foundation Home Page

President’s Letter:

Photo of Scott Johnson

Scott Johnson, Myelin Repair Foundation President, CEO and Founder … waiting for a cure since 1976

Dear Friends and Supporters of MRF,

Our goal and sole focus at MRF has always been to accelerate myelin repair treatments to MS patients. To that end we have recently initiated an innovative new effort to identify biomarkers for use in myelin repair drug development and clinical trials. The current lack of molecular biomarkers greatly hinders the pace of myelin repair treatment availability.

A biomarker, or biological marker, refers to a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated to examine pharmacologic responses to a therapeutic intervention. In medicine, a biomarker can be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may indicate an infection. More specifically, a biomarker indicates a change in expression or state of a protein that correlates with the susceptibility of the disease to a given treatment.

If a treatment alters the biomarker, which has a direct connection to improved health, the biomarker serves as a surrogate endpoint for evaluating clinical benefit. Some of the main areas in which molecular biomarkers are used in the drug development process are: early drug development studies, safety studies, proof of concept studies, and molecular profiling.

In short, disease-related biomarkers give an indication of the probable effect of treatment both in pre-clinical studies and in trials on patients.

But, identifying biomarkers is very difficult, expensive and time consuming. The process requires a myriad of expertise and technology as well as creativity. And while having biomarkers of myelin repair would greatly benefit research in academia and at all the companies with myelin repair programs, it is very difficult for any one entity to undertake. The task is perfectly suited to MRF. We have a track record of tackling challenging and complex tasks by building effective collaborations. MRF began this new initiative by gathering information, building relationships, developing strategy and getting the top experts involved.

Thank you for your support, I look forward to providing updates as we make progress.

Sincerely,

Scott

Focus on Biomarkers

The Myelin Repair Foundation is identifying biomarkers to help accelerate myelin repair treatments. Learn more about the importance of biomarkers and the role they play in getting treatments to patients.